Migraine

Alzheimer's

1 billion people in the world suffer from migraine. That makes it the most debilitation neurological disease and the third most common of all diseases and yet treatment options are limited and do not address the root causes.

1 in 3 seniors die from Alzheimer's dementia and its prevalence increases by 123% every year. In 2018 costs for society reached over 1 trillion $ and yet their are no treatment options, yet.

Therapeutic Areas

 

Management & Board of Directors

Dr. Elena Gross

Founder & CEO/CSO

Dr. Elena Gross holds a BSc in Psychology (University of York), an MSc in Neuroscience (University of Oxford) a PhD (Dr. sc. med) in Clinical Research (University of Basel) and is currently enrolled to complete her MBA (University of Cambridge). She used to be a chronic migraine patient and founded KetoSwiss AG. She is the inventor of two patents.

  • Dr. Elena Gross Li

Matthias Währen

Chief Financial Officer

Matthias Währen is ex-CFO & member of the Executive Committee of Givaudan SA for twelve years, previously Global Head of Finance at Roche Vitamin Division, Finance Director Roche USA, Roche Japan,  Roche Korea (amongst others).

  • Matthias Waehren Li

Dr. Sebastian Hersberger

Chief Operating Officer

Dr. Sebastian Hersberger holds a PhD in Financial Management and has more than ten years of experience working with companies on topics such as driving extensive and sustainable growth, designing and implementing business operations and effective operational & financial procedures

  • Dr. Sebastian Hersberger Li

Dr. Adrian Soto

Chief Medical Officer

Dr. Adrian Soto is a Medical Doctor specialized in the field of internal medicine. Currently, he is a doctoral student at the University of Oxford researching the potential clinical applications of exogenous ketone bodies.  Adrian has successfully led various clinical trials.

  • Dr. Adrian Soto

Aaron Neuville

Chief Marketing Officer

Aaron Neuville collected more than 7 years of professional experience in developing international online go-to-market strategies as well as marketing campaigns for SMEs in Europe, du-ring his tenures at Google and EY. He studied mechanical engineering, Eco-nomics and Public Policy in Darm-stadt, Berlin and Tokyo 

  • ellivuen Li
 

Board of Advisors

 

Peter Stähli

Business & Strategy Advisor

Founder of several startups and the Swiss Economic Forum (of which he was CEO until 2016). Moreover, Peter successfully advised several startups and owns a very strong national and international network.

  • PS-Li

Prof. Dr. Jan Schoenen

Scientific & Clinical Advisor

Former President of the International Headache So-ciety & Belgian Neurological Society, research Director, full Professor at Liège Uni-versity & Associate Editor of Cephalalgia. World expert on metabolism and migrai-ne, with over 908 publica-tions (H index: 56 after 1996), 92 book chapters & 4 books

  • JS-Li

Dr. Andreas Schulze

Business, Finance & Strategy Advisor

Dr. Andreas Schulze holds various management posi-tions also in Venture Capital

(DEWB AG,  BioMed Part-ners), conduct-ing several due diligences, evolving portfolio companies & pre-pares them for transaction. Since 2014 he is owner of the consulting firm, Marsa Corporate Finance.

  • AS-Li

Dr. Zameel Cader

Strategic Advisor

Dr. Zameel Cader is cur-rently Head of the Oxford Translational Molecular Neu-roscience Group. He is a senior clinical academic researcher, with a track record in translational me-dical research.

He furthermore successfully lead large-scale academic/ industry partnerships with societal impact.

  • ZC-Li

Dr. Thomas Beck

Business & Strategy Advisor

Dr. Thomas Beck  was the former head of the Nestle research centre and is now head of R&D at DSM. He brings a wealth of experience in the supplement / nutraceutical and life s/ health sciences industry and an extensive network.

  • ZC-Li
 

Outsourced Functions

Dr. Nicolas Mosimann

Legal

  • NM-Li

Dr. Philipp Marchand

Patent Issues

  • PM-Li

Sebastian Melchor

Complex Regulatory Affairs

  • SM-Li

Urs Santschi

Finance & Accounting

  • US-Li
 

Investors / Partnering

While we are increasingly able to preserve the body, we have little tools to combat neurological diseases. Most brains are not designed to thrive on a modern western diet. KetoSwiss aims to reintroduce ketone bodies into modern life with an easily implemented solution.

Inverstors

KetoSwiss has developed a novel therapeutic for the dietary-preventive therapy of higher-frequency migraines and related diseases that are characterized by a metabolic dysfunction. We set out to become the market leader in the medical food area, while the product might be further developed into a drug – considering a multi-billion market opportunity.

KetoSwiss is equipped with a strong team and advisors from various backgrounds and benefits from more than a century of extensive healthcare experience. 

Partnering

KetoSwiss embraces partnerships to advance the discovery and development of novel, innovative products for civilisation diseases with a metabolic component, especially neurological diseases.

We are convinced that combining ideas and resources with our partners will bring products to markets with unmet needs faster and more efficiently.

Help us fuel brains!

To find out more about upcoming investment and partnership opportunities, get in touch with us now.

© 2019 by KetoSwiss AG